Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis
Open Access
- 8 December 2016
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (2) , 376-378
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational studyAlimentary Pharmacology & Therapeutics, 2016
- Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver TransplantationInflammatory Bowel Diseases, 2016
- Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing CholangitisJournal of Crohn's and Colitis, 2015
- Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center CohortPLOS ONE, 2015
- Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantationLiver Transplantation, 2015
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipientsAlimentary Pharmacology & Therapeutics, 2012
- The safety and efficacy of antitumour necrosis factor‐alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case seriesAlimentary Pharmacology & Therapeutics, 2012
- Diagnosis and Management of Primary Sclerosing CholangitisHepatology, 2010
- The Natural History of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis after Liver Transplantation – a Single-Centre ExperienceCanadian Journal of Gastroenterology and Hepatology, 2010